PYXS vs. DSGN, RNAC, DRUG, NGNE, HUMA, PBYI, ACB, GLUE, FHTX, and AVIR
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Design Therapeutics (DSGN), Cartesian Therapeutics (RNAC), Bright Minds Biosciences (DRUG), Neurogene (NGNE), Humacyte (HUMA), Puma Biotechnology (PBYI), Aurora Cannabis (ACB), Monte Rosa Therapeutics (GLUE), Foghorn Therapeutics (FHTX), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.
Pyxis Oncology vs. Its Competitors
Pyxis Oncology (NASDAQ:PYXS) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.
In the previous week, Pyxis Oncology had 17 more articles in the media than Design Therapeutics. MarketBeat recorded 19 mentions for Pyxis Oncology and 2 mentions for Design Therapeutics. Pyxis Oncology's average media sentiment score of 0.97 beat Design Therapeutics' score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media.
Design Therapeutics' return on equity of -27.15% beat Pyxis Oncology's return on equity.
Pyxis Oncology presently has a consensus target price of $8.67, suggesting a potential upside of 532.60%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Design Therapeutics.
Pyxis Oncology has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.
39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 10.6% of Pyxis Oncology shares are owned by insiders. Comparatively, 23.5% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Design Therapeutics has lower revenue, but higher earnings than Pyxis Oncology. Design Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Pyxis Oncology and Design Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Pyxis Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:PYXS) was last updated on 8/26/2025 by MarketBeat.com Staff
MarketBeat All Access